Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

December 15, 2020December 15, 2020

$3.2M NIH Grant Supports Development of New Approach to Target ‘Invisible’ Residual Tumors

News

A $3.2-million grant from the National Institutes of Health has been awarded to the collaborative work between Northeastern University’s Spring Lab and Cellaria into a new method of eliminating the ... Read more

November 19, 2020November 19, 2020

Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women

News

The University of Texas’ MD Anderson Cancer Center, in collaboration with the National Cancer Institute and Golfers Against Cancer, is evaluating the usefulness of a blood test called CA-125 at detecting ovarian cancer ... Read more

November 10, 2020January 12, 2021

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

News

The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

September 24, 2020September 24, 2020

Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer

News

Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

May 12, 2020January 12, 2021

FDA Approves Lynparza Combo as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. This ... Read more

April 30, 2020May 12, 2020

FDA Approves Zejula as First-line Maintenance Therapy for Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a first-line maintenance therapy for women with advanced ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA mutation status. This indication ... Read more

February 7, 2020February 7, 2020

New Progress Made in Developing Bio-ink for 3-D Printing Functional Human Ovaries, Researchers Report

News

Researchers at Northwestern University have identified and mapped the location of structural proteins within pig’s ovaries, which closely resemble human ovaries. This will help the development of an ovary-specific bio-ink ... Read more

January 23, 2020February 6, 2020

FDA Asked to Approve Test of Ovarian Cancers Likely to Respond to Zejula Maintenance Therapy

News

Myriad Genetics has filed a supplementary premarket approval (sPMA) application with the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to identify advanced ovarian cancer patients more likely ... Read more

December 4, 2019

Rubraca Reimbursement Approved in Italy for Women With Relapsed Platinum-sensitive Ovarian Cancer

News

The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, ... Read more

November 4, 2019

OTL38 ‘Lights up’ Ovarian Cancer Cells, Helping Surgeons to Remove Them, Phase 2 Study Shows

News

OTL38, a tumor-specific fluorescent compound that “lights up” ovarian tumor tissue during surgery, helped doctors to detect and remove cancer cells that would otherwise be missed, final results of a ... Read more